A targeted genome association study examining transient receptor potential ion channels, acetylcholine receptors, and adrenergic receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. — CFSMEATLAS
A targeted genome association study examining transient receptor potential ion channels, acetylcholine receptors, and adrenergic receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
Johnston, Samantha, Staines, Donald, Klein, Anne et al. · BMC medical genetics · 2016 · DOI
Quick Summary
Researchers looked at specific genes that control how nerves and muscles communicate in people with ME/CFS compared to healthy people. They found that people with ME/CFS were more likely to carry a particular genetic variation in a gene called ADRA1A, which is involved in how the body responds to stress. This discovery suggests that differences in how the nervous system is wired genetically may play a role in ME/CFS.
Why It Matters
This is the first genetic study to identify a potential association between ADRA1A and ME/CFS, targeting genes involved in neurological and autonomic function—key systems affected in the disease. Understanding genetic variations in stress-response receptors could lead to better explanations for why some people develop ME/CFS and may eventually guide treatment development targeting these pathways.
Observed Findings
SNP rs2322333 in ADRA1A was found at higher frequency in heterozygous form in CFS/ME patients (45.3%) compared to healthy controls (23.4%).
Homozygous minor allele (AA) genotype was substantially less common in CFS/ME patients (4.2%) than in healthy controls (24.7%).
Of 950 SNPs analyzed across target gene families, 60 showed significant association with CFS/ME before multiple testing correction.
After applying FDR and Bonferroni corrections for multiple testing, ADRA1A remained the primary identified association.
The study cohort comprised 95 CFS/ME patients (mean age 45.8 years, 69% female) and 77 healthy controls (mean age 42.3 years, 63% female).
Inferred Conclusions
Adrenergic receptor α1 (ADRA1A) genetic variants may be associated with ME/CFS susceptibility or phenotype.
The genotype distribution pattern suggests a potential protective effect of the homozygous minor allele in controls, or conversely, increased disease association with other genotype classes.
Further functional studies of adrenergic receptor biology may help explain neurological and autonomic symptoms characteristic of ME/CFS.
Remaining Questions
Does the ADRA1A genetic variation actually cause ME/CFS, or is it a marker for another causal variant in nearby genes?
What This Study Does Not Prove
This study does not prove that ADRA1A genetic variants cause ME/CFS; it only shows an association in this particular population. The findings require replication in larger, independent cohorts before clinical significance can be established. The study also does not explain how these genetic differences actually contribute to ME/CFS symptoms or whether the genetic variation is truly causal or simply correlated with disease.
Tags
Symptom:Sensory Sensitivity
Biomarker:Gene Expression
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only